*Bernard and Shirlee Brown Glaucoma Research Laboratory, Edward S. Harkness Eye Institute, Columbia University Irving Medical Center, New York, NY
†Department of Ophthalmology, Otorhinolaryngology and Head and Neck Surgery, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, SP, Brazil
‡Department of Ophthalmology, University of Alabama-Birmingham, Birmingham, AL
§Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology, and Shiley Eye Institute University of California-San Diego, La Jolla, CA
B.M.: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brasília, DF, Brazil. C.G.D.M.: Consultant: Belite—San Diego, CA; Reichert—Buffalo, NY; Novartis—East Hanover, NJ; Galimedix Therapeutics Inc.—Kensington, MD; Carl Zeiss Meditec Inc.—Dublin, CA; Perfuse Therapeutics—San Francisco, CA; Recipient: Heidelberg Engineering GmbH—Heidelberg, Germany; Topcon Medical Systems—Oakland, NJ. J.S.P.: Consultant: Allergan, Inc.—Dublin, Ireland. G.A.C.: No financial disclosures. C.A.G.: Financial support: Research to Prevent Blindness, New York, NY; Heidelberg Engineering GmbH—Heidelberg, Germany; National Eye Institute—Bethesda, MD; Eyesight Foundation of Alabama-Birmingham, AL. M.A.F.: National Eye Institute—Bethesda, MD; EyeSight Foundation of Alabama, AL; Research to Prevent Blindness—New York NY; Heidelberg Engineering GmbH—Heidelberg, Germany. R.N.W.: Consultant: Aerie Pharmaceuticals—Pittsburgh, PA; Allergan Inc—Dublin, Ireland; Bausch Healthcare, Inc.—Bridgewater, NJ; Equinox—Newport Beach, CA; Eyenovia—New York NY; Financial support: Heidelberg Engineering GmbH—Heidelberg, Germany; Carl Zeiss Meditec Inc.—Dublin, CA; Centervue—Fremont, CA; Konan Medical—Irvine, CA; Optovue Inc.—Fremont, CA; Bausch Healthcare, Inc.—Bridgewater, NJ.: Topcon Medical Systems—Oakland, NJ Patent: Toromedes, Inc.—La Jolla, CA; Carl Zeiss Meditec Inc.—Dublin, CA. L.M.Z.: Financial support:—Carl Zeiss Meditec Inc.—Dublin, CA; Heidelberg Engineering GmbH—Heidelberg, Germany; Optovue Inc.—Fremont, CA; Topcon Medical Systems—Oakland, NJ; National Eye Institute—Bethesda, MD; Heidelberg Engineering GmbH—Heidelberg, Germany. Patent: Carl Zeiss Meditec Inc.—Dublin, CA. J.M.L.: Consultant: Aerie Pharmaceuticals, Inc.—Pittsburgh, PA; Eyenovia—New York NY; Heidelberg Engineering, GmBH—Heidelberg, Germany; NY;—Laval, Canada; Novartis—East Hanover, NJ; Galimedix Therapeutics Inc.—Kensington, MD; Bausch Healthcare, Inc.—Bridgewater, NJ; Allergan, Inc.—Dublin, Ireland.
Financial support by Heidelberg Engineering, GmBH—Heidelberg, Germany; National Eye Institute—Bethesda, MD; Research to Prevent Blindness, New York, NY. National Eye Institute Grants U10EY14267, EY08208, EY11008, EY019869, EY13959, 1EY027510, EY029058, EY025253 (CGDM)—Bethesda, MD; Eyesight Foundation of Alabama-Birmingham, AL; Alcon Laboratories Inc.—Fort Worth, TX; Allergan Inc.—Dublin, Ireland; Pfizer Inc.—New York, NY; Merck Inc.—Rahway, NJ; Santen Inc.—Osaka, Japan; unrestricted departmental grant from Research to Prevent Blindness, New York, NY (Department of Ophthalmology, Columbia University Medical Center and Department of Ophthalmology, University of California San Diego), Edith C. Blum Foundation, New York, NY, Bernard Schwartz Travel Grant from the American Glaucoma Society, San Francisco, CA.
Disclosure: The authors declare no conflict of interest.
Reprints: Carlos G. de Moraes, MD, PhD, MPH, Edward S. Harkness Eye Institute, 635 West 165th Street, Box 69, New York, NY 10032 (e-mail: [email protected]).
